Several other EGFR-TKI have been trialed in patients with EGFR-mutated metastatic NSCLC (such as dacomitinib and erlotinib) but with a high incidence and severity of adverse events [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.